Physician profile
Michael Anderson
NPI 1992285605
$2,968.78
in general payments reported to CMS, 2019-2025
22 companies · $1,300 in 2025
The $1,300 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $245 · 2023: $238 · 2024: $1,062 · 2025: $1,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,327 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,327.08 |
| Education | $272.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.71 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $398.72 | 2023-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $282.80 | 2024-2025 | Tremfya |
| Amgen INC. | $252.63 | 2021-2024 | Otezla |
| Leo Pharma INC. | $218.61 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $124.89 | 2025 | |
| Novartis Pharmaceuticals Corporation | $118.66 | 2024-2025 | |
| Ucb, INC. | $115.00 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $98.53 | 2024-2025 | Aklief, Nemluvio |
| Lilly USA, LLC | $96.51 | 2024-2025 | Ebglyss, Taltz |
| Dermavant Sciences, INC. | $90.24 | 2023-2024 | Vtama |
| Incyte Corporation | $76.02 | 2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $57.40 | 2023-2025 | Sotyktu |
| Pfizer INC. | $54.93 | 2025 | |
| Biofrontera INC. | $47.65 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $41.62 | 2025 | Ycanth |
| Organon LLC | $36.26 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $33.80 | 2024-2025 | Zoryve |
| Boston Scientific Corporation | $30.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.86 | 2023 | Spevigo |
| Merck Sharp & Dohme LLC | $18.30 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.17 | 2025 | Cabtreo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.